MNKD

MannKindA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

28%

Probability

Target price

$5.25

+30.0% vs current

Most likely

Base case

47%

Probability

Target price

$4.45

+10.1% vs current

B-

Bear case

25%

Probability

Target price

$3.15

-22.0% vs current

AI sentiment snapshot

Latest data as of 2026-07-18

AI commentary

The setup remains mildly constructive but event-driven. Primary support is strong for the Afrezza approval and upcoming Furoscix decision, while recent news flow is thin and social coverage is unavailable. The $4.03 anchor price leaves meaningful binary-event sensitivity, warranting monitoring rather than high-conviction positioning.

RankAlpha Sentiment Codex - 2026-07-18

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-07-26eventFuroscix ReadyFlow Autoinjector FDA decisionHigh impact

MannKind reported a July 26, 2026 PDUFA target action date for the Furoscix ReadyFlow Autoinjector. Approval could add a commercial growth lever; delay or rejection would pressure the event-driven thesis. [#SEC-8K-2026-05-06]

2026-08-31catalystAfrezza pediatric approval now requires launch-uptake proofHigh impact

FDA approval expanded Afrezza use to children and adolescents aged 6 and older. The next evidence gap is commercial uptake, not regulatory approval. [#8-K-2026-06-02]

2026-09-30catalystPulmonary pipeline and partnership executionHigh impact

Nintedanib DPI is advancing toward Phase 2, with INFLO-1 topline data expected in Q3 2026, while the expanded United Therapeutics ralinepag DPI collaboration provides additional development support. Execution and clinical validation remain unproven. [#SEC-8K-2026-05-06]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology